esophageal cancer
Conditions
Interventions
Esketamine group :Esketamine Group (S Group): Before the skin incision, administer 0.25 mg/kg of esketamine intravenously, diluted to 5 ml. During the surgery, infuse esketamine at a rate of 0.125 mg/
control group:Control Group (C Group): Before the skin incision, administer an equal volume of normal saline (5 ml) intravenously. During the surgery, infuse normal saline at the same rate as in the S
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Patients undergoing elective minimally invasive McKeown esophageal surgery under general anesthesia; (2) Age = 18 years old; (3) ASA grades I-III; (4) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed with mental illnesses; (2) Patients who are unable to communicate due to preoperative cognitive or language impairments; (3) Patients with chronic pain or a history of opioid abuse before surgery, as well as a history of drug use or alcohol abuse within the past 3 months; (4) Patients known to be allergic to esketamine; (5) There are any contraindications for the use of esketamine injection, including: severe risk of elevated blood pressure or intracranial pressure, high intraocular pressure (glaucoma) or penetrating eye injury, poorly controlled or untreated hypertension (systolic/diastolic blood pressure exceeding 180/110 mmHg at rest), untreated or insufficiently treated hyperthyroidism (hyperthyroidism), pregnancy or lactation; (6) Unstable angina or myocardial infarction occurred within the past 6 months; (7) Acute lung injury or acute respiratory distress syndrome within 3 months prior to surgery; (8) Critical illnesses, including severe liver dysfunction (such as liver failure), severe coronary heart disease, chronic kidney failure (glomerular filtration rate<30ml/min), and heart failure (NYHA functional class = IV); (9) Patients have been participated in clinical studies of other drugs or medical devices in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QoR-15 Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| QoR-15 Score;Resting and Exercise NRS Score;BPI;HADS score;Clavien-Dindo score; | — |
Countries
China
Contacts
Public ContactHai Yu
West China Hospital of Sichuan University
Outcome results
None listed